New Phase II/III study will evaluate ivonescimab plus chemotherapy against existing immunotherapy-based treatments, building ...

The IMPACT31 trial will enrol 90 high-risk liver cancer patients across the US and Asia-Pacific to evaluate GNOS-PV02 ...

Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal ...

New CAS Connections integration combines over 150 years of curated scientific knowledge with CAS Newton’s agentic AI ...

Medical device makers went digital to stay audit-ready. Yet their device history records are still being stitched together by ...

ESTEVE CDMO, Esteve Healthcare contract development and manufacturing organization, is strengthening its presence in Asia ...

NeuroXT Inc., a medical device manufacturer, announced that NEXT-Cue, its AI-based Software as a Medical Device (SaMD) ...

The new fiscal year is already two days into its own ledger. On 2 October 2026, FDA issued a letter to Hanlim Pharm in Yongin ...

Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone ...

Operating profit reaches KRW 640 billion as Plant 5 ramp-up and US operations strengthen performance, prompting the CDMO ...

Oracle announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible ...

Filled marks show published items; half marks show documents announced or scheduled but not yet public. The device column is ...